J. Carlet, Overcoming global antimicrobial resistance. AMR control. WAAAR 2015, Carlet.pdf), 2015.

E. Kutter, . Kuhl, . Sj, and S. Abedon, Re-establishing a place for phage therapy in western medicine, Future Microbiology, vol.10, issue.5, pp.685-693, 2015.
DOI : 10.2217/fmb.15.28

M. Merabishvili, J. Pirnay, and G. Verbeken, Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials, PLoS ONE, vol.158, issue.3, p.4944, 2009.
DOI : 10.1371/journal.pone.0004944.s002

R. Mie¸dzybrodzkimie¸mie¸dzybrodzki, J. Borysowski, and W. , Clinical Aspects of Phage Therapy, Adv Virus Res, vol.83, pp.73-121, 2012.
DOI : 10.1016/B978-0-12-394438-2.00003-7

J. Pirnay, B. Blasdel, and L. Bretaudeau, Quality and Safety Requirements for Sustainable Phage Therapy Products, Pharmaceutical Research, vol.313, issue.7, pp.2173-2182, 2015.
DOI : 10.1007/s11095-014-1617-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452253

J. Pirnay, D. Vos, D. Verbeken, and G. , The Phage Therapy Paradigm: Pr?t-?-Porter or Sur-mesure?, Pharmaceutical Research, vol.2, issue.4, pp.934-941, 2011.
DOI : 10.1038/nrmicro822

M. Witzenrath, Time for Tailored Antimicrobials, Critical Care Medicine, vol.43, issue.6, pp.1346-1353, 2015.
DOI : 10.1097/CCM.0000000000001038